



KAREN L. SMITH, MD, MPH  
Director & State Health Officer

State of California—Health and Human Services Agency  
California Department of Public Health



EDMUND G. BROWN JR.  
Governor

OFFICE OF AIDS  
AIDS Drug Assistance Program (ADAP)

Management Memorandum  
Memorandum Number: 2015-18

**Date:**           **October 19, 2015**

**TO:**             **LOCAL ADAP COORDINATORS  
ADAP ENROLLMENT WORKERS**

**SUBJECT:   ADDITION OF ELVITEGRAVIR (VITEKTA™) TO THE ADAP  
FORMULARY**

**Effective October 16, 2015**, elvitegravir (Vitekta®), available in 85 mg and 150 mg tablets, has been added to the ADAP formulary. Elvitegravir is a once-daily integrase inhibitor antiretroviral (ARV) drug that can be used as an alternative to existing integrase inhibitor ARVs already on the ADAP formulary.

Elvitegravir was approved by the federal Food and Drug Administration on September 24, 2014 for use in individuals infected with the human immunodeficiency virus (HIV). The drug did not become commercially available until March of 2015 and cost neutral for ADAPs until September 2015.

With the addition of elvitegravir, ADAP has 194 drugs on the formulary. If you have any questions regarding the addition of this ARV to the ADAP formulary, please contact me at (916) 449-5943 or Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Celia Banda-Brown, Chief  
ADAP Section  
Office of AIDS